Skip to main content

Table 1 Baseline characteristics of the patients before and after propensity score matching

From: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

 

Before propensity score matching (n = 477)

After propensity score matching §(n = 220)

S-1 (n = 331)

XELOX (n = 146)

p value*

Absolute‡ Standardized difference in %

S-1 (n = 110)

XELOX (n = 110)

p value†

Absolute‡ Standardized difference in %

Age (years)

  < 65

181 (54.7)

104 (71.2)

0.001

34.7

70 (63.6)

68 (61.8)

0.889

3.7

  ≥ 65

150 (45.3)

42 (28.8)

 

34.7

40 (36.4)

42 (38.2)

 

3.7

Sex

 Male

225 (68.0)

101 (69.2)

0.795

2.6

76 (69.1)

76 (69.1)

> 0.999

< 0.001

 Female

106 (32.0)

45 (30.8)

 

2.6

34 (30.9)

34 (30.9)

 

< 0.001

ECOG

 0

241 (72.8)

124 (84.9)

0.004

30.0

86 (78.2)

89 (80.9)

0.738

6.7

  ≥ 1

90 (27.2)

22 (15.1)

 

30.0

24 (21.8)

21 (19.1)

 

6.7

ASA score

 1 to 2

308 (93.1)

138 (94.5)

0.549

3.4

100 (90.9)

103 (93.6)

0.615

9.2

  ≥ 3

23 (6.9)

8 (5.5)

 

3.4

10 (9.1)

7 (6.4)

 

9.2

Location

 EGJ

11 (3.3)

7 (4.8)

0.437

7.4

107 (97.3)

108 (98.2)

> 0.999

6.1

 Other

320 (96.7)

139 (95.2)

 

7.4

3 (2.7)

2 (1.8)

 

6.1

Stage (AJCC 7th edition)

 IIA

109 (32.9)

5 (3.4)

< 0.001

82.8

3 (2.7)

4 (3.6)

0.982

5.2

 IIB

73 (22.1)

19 (13.0)

 

23.9

21 (19.1)

19 (17.3)

 

4.7

 IIIA

52 (15.7)

39 (26.7)

 

27.2

28 (25.5)

26 (23.6)

 

4.2

 IIIB

53 (16.0)

48 (32.9)

 

40.0

33 (30.0)

34 (30.9)

 

2.0

 IIIC

44 (13.3)

35 (24.0)

 

27.7

25 (22.7)

27 (24.5)

 

4.3

T stage

 T1

26 (7.9)

3 (2.1)

0.001

27.0

4 (3.6)

3 (2.7)

> 0.999

5.2

 T2

51 (15.4)

10 (6.8)

 

27.5

8 (7.3)

8 (7.3)

 

0.0

 T3

129 (39.0)

56 (38.4)

 

1.3

40 (36.4)

40 (36.4)

 

0.0

 T4a,b

125 (37.8)

77 (52.7)

 

30.4

58 (52.7)

59 (53.6)

 

1.8

N stage

 N0

87 (26.3)

9 (6.2)

< 0.001

56.7

9 (8.2)

9 (8.2)

0.986

0.0

 N1

67 (20.2)

28 (19.2)

 

2.7

16 (14.5)

17 (15.5)

 

2.5

 N2

103 (31.1)

38 (26.0)

 

11.3

39 (35.5)

36 (32.7)

 

5.8

 N3

74 (22.4)

71 (48.6)

 

57.1

46 (41.8)

48 (43.6)

 

3.7

Number of dissected lymph nodes

 mean ± sd

47.0 ± 18.8

52.4 ± 17.1

< 0.001

30.0

51.4 ± 21.4

51.5 ± 16.5

0.493

0.7

 median (IQR)

43 (35–55)

52 (39–65)

  

45 (37–64)

52 (39–62)

  

LNR group

 LNR 0

88 (26.6)

9 (6.2)

< 0.001

40.2

68 (61.8)

66 (60.0)

0.89

3.7

 LNR 1

127 (38.4)

49 (33.6)

 

40.2

42 (38.2)

44 (40.0)

 

3.7

 LNR 2

78 (23.6)

47 (32.2)

      

 LNR 3

38 (11.5)

41 (28.1)

< 0.001

57.4

9 (8.2)

9 (8.2)

0.994

0.0

Tumor size (cm)

   

10.0

36 (32.7)

35 (31.8)

 

1.9

  < 6

250 (75.5)

83 (56.8)

 

19.3

39 (35.5)

41 (37.3)

 

3.8

  ≥ 6

81 (24.5)

63 (43.2)

 

42.6

26 (23.6)

25 (22.7)

 

2.2

Differentiation

 Well to moderately

114 (34.4)

34 (23.3)

0.015

24.8

25 (22.7)

28 (25.5)

0.753

6.4

 Poorly

217 (65.6)

112 (76.7)

 

24.8

85 (77.3)

82 (74.5)

 

6.4

Lauren classification

 Intestinal

118 (35.6)

39 (26.7)

0.111

19.4

30 (27.3)

34 (30.9)

0.732

8.0

 Diffuse

96 (29.0)

43 (29.5)

 

1.0

37 (33.6)

32 (29.1)

 

9.8

 Mixed

117 (35.3)

64 (43.8)

 

17.4

43 (39.1)

44 (40.0)

 

1.9

Lymphovascular invasion

 no

90 (27.2)

13 (8.9)

< 0.001

50.2

8 (7.3)

13 (11.8)

0.359

8.9

 yes

241 (72.8)

133 (91.1)

 

50.2

102 (92.7)

97 (88.2)

 

8.9

Perineural invasion

 no

161 (48.6)

49 (33.6)

0.002

30.9

40 (36.4)

39 (35.5)

> 0.999

1.9

 yes

170 (51.4)

97 (66.4)

 

30.9

70 (63.6)

71 (64.5)

 

1.9

Completion of planned chemotherapy

 no

69 (20.8)

42 (28.8)

0.059

18.4

25 (22.7)

26 (23.6)

> 0.999

2.1

 yes

262 (79.2)

104 (71.2)

 

18.4

85 (77.3)

84 (76.4)

 

2.1

CEA (ng/ml)

  < 5

315 (95.2)

140 (95.9)

0.728

3.5

106 (96.4)

106 (96.4)

> 0.999

< 0.001

  ≥ 5

16 (4.8)

6 (4.1)

 

3.5

4 (3.6)

4 (3.6)

 

< 0.001

CA 19–9 (U/ml)

  < 37.0

308 (93.1)

132 (90.4)

0.320

9.6

100 (90.9)

102 (92.7)

0.806

9.7

  ≥ 37.0

23 (6.9)

14 (9.6)

 

9.6

10 (9.1)

8 (7.3)

 

9.7

  1. Data are presented as the n (%) for categorical variable, unless otherwise indicated
  2. *P value from Wilcoxon rank sum test for continuous variables or Chi-square test, for categorical variables in before Propensity score matching data
  3. †P value from Wilcoxon signed rank sum test for continuous variables or Chi-square test, for categorical variables in matched data
  4. ‡no covariates would be considered imbalanced if the threshold was set at either 0.10 (Normand et al. 2001) or 0.25 (Rubin 2001)
  5. §matched using digit-based greedy (“greedy”)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us